Clinical trials recruiting for Lupus Nephritis

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
  NCT06308978 · Phase: Phase 1 · Ages: 12 Years to 70 Years · Sex: All (male and female) · 21 locations
• A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
  NCT06557265 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 19 locations
• A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
  NCT07570862 · Phase: Phase 2 · Ages: 12 Years to 70 Years · Sex: All (male and female) · 9 locations
• A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
  NCT06925542 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 16 locations
• A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis
  NCT06406205 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations
• A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
  NCT06581198 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 101 locations
• A Study of Telitacicept in Lupus Nephritis
  NCT05680480 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 45 locations
• A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
  NCT07598396 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
  NCT05039619 · Phase: Phase 2 · Ages: 5 Years to 17 Years · Sex: All (male and female) · 43 locations
• Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone, Mycofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and Prednisolone
  NCT07760480 · Phase: Phase 4 · Ages: 16 Years to 70 Years · Sex: All (male and female) · 1 location
• Biomarker Development for Autoimmune Disorders Involving the Kidneys
  NCT07666711 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis
  NCT06785519 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children
  NCT06904729 · Phase: Phase 3 · Ages: 6 Years to 18 Years · Sex: All (male and female) · 1 location
• Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus
  NCT05443516 · Phase: Not specified · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis
  NCT06167174 · Phase: Not specified · Ages: 16 Years to 60 Years · Sex: All (male and female) · 1 location
• Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
  NCT06350110 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• High Quality Evidence of Chinese Lupus Nephritis (HELP)
  NCT03001973 · Phase: Not specified · Ages: 14 Years and older · Sex: All (male and female) · 1 location
• Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF
  NCT04702256 · Phase: Phase 3 · Ages: 14 Years and older · Sex: All (male and female) · 1 location
• KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
  NCT03929887 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 6 locations
• LUPKYNIS Drug-use Results Survey
  NCT07053891 · Phase: Not specified · Ages: 15 Years and older · Sex: All (male and female) · 1 location
• Lupus Landmark Study: A Prospective Registry and Biorepository
  NCT05934149 · Phase: Not specified · Ages: 18 Years to 110 Years · Sex: All (male and female) · 25 locations
• Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis
  NCT05207358 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
  NCT07053800 · Phase: Phase 2 · Ages: 12 Years to 65 Years · Sex: All (male and female) · 15 locations
• PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
  NCT07611214 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 27 locations
• Per-protocol Repeat Kidney Biopsy in Incident Cases of Lupus Nephritis
  NCT04449991 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
  NCT06434363 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
  NCT06711887 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 47 locations
• Phase IIa Study for IPG11406 in Patients With Lupus Nephritis
  NCT06717815 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 17 locations
• RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
  NCT06121297 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 23 locations
• RY_SW01 Cell Injection Therapy in Active Lupus Nephritis
  NCT06058078 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
  NCT06277427 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients
  NCT06631404 · Phase: Not specified · Ages: 18 Years to 50 Years · Sex: All (male and female) · 1 location
• Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
  NCT01802034 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
  NCT07523542 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
  NCT06155604 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
  NCT07225387 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 7 locations
• Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
  NCT06497387 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
  NCT06497361 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
  NCT05268289 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 103 locations
• Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
  NCT06527872 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Systemic Immune Inflammatory Index in Systemic Lupus Erythematosus
  NCT06796569 · Phase: Not specified · Ages: 16 Years and older · Sex: All (male and female) · 1 location
• The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
  NCT06285279 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis
  NCT02954939 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
  NCT05538208 · Phase: Phase 2 · Ages: 8 Years to 20 Years · Sex: All (male and female) · 19 locations
• Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells
  NCT03673748 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
  NCT07109986 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• US Zamto-cel Autoimmune Diseases
  NCT06708845 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• VIBRANT: VIB4920 for Active Lupus Nephritis
  NCT05201469 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Wellness & Workforce Solution for Lupus/Lupus Nephritis
  NCT06217107 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 1 location

Related conditions

Trials recruiting for Lupus Nephritis often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Lupus Nephritis trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.